Si M. Zhang

Stockholm, AB 14186, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Allosteric targeting with antiviral nucleotide analogs allows fine-tuning of SAMHD1 dNTPase activity.

Allosteric targeting with antiviral nucleotide analogs allows fine-tuning of SAMHD1 dNTPase activity.

Journal: The Journal of biological chemistry
Published: October 26, 2025

Uridine cytidine kinases govern molnupiravir bioactivation and anti-SARS-CoV-2 activity.

Uridine cytidine kinases govern molnupiravir bioactivation and anti-SARS-CoV-2 activity.

Journal: PLoS pathogens
Published: October 23, 2025

IMPDH inhibition enhances cytarabine efficacy in SAMHD1-expressing leukaemia cells via guanine nucleotide depletion.

IMPDH inhibition enhances cytarabine efficacy in SAMHD1-expressing leukaemia cells via guanine nucleotide depletion.

Journal: Molecular oncology
Published: July 16, 2025

Repurposing Asparaginase Therapy to Target Cisplatin-Resistant Cancer Cells.

Repurposing Asparaginase Therapy to Target Cisplatin-Resistant Cancer Cells.

Journal: Fundamental & clinical pharmacology
Published: June 18, 2025

The N-terminal SAM domain of the dNTPase SAMHD1 is not required for inhibition by small molecule TH6342.

The N-terminal SAM domain of the dNTPase SAMHD1 is not required for inhibition by small molecule TH6342.

Journal: Nucleosides, nucleotides & nucleic acids
Published: June 03, 2024

Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel.

Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel.

Journal: iScience
Published: November 12, 2022

Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM.

Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM.

Journal: Nature communications
Published: October 05, 2022

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Journal: Cell death & disease
Published: August 03, 2022

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Journal: Cell death & disease
Published: May 06, 2021

NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir.

NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir.

Journal: Cell chemical biology
Published: March 22, 2021

Crystal structures of NUDT15 variants enabled by a potent inhibitor reveal the structural basis for thiopurine sensitivity.

Crystal structures of NUDT15 variants enabled by a potent inhibitor reveal the structural basis for thiopurine sensitivity.

Journal: The Journal of biological chemistry
Published: January 20, 2021

Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress.

Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress.

Journal: Nature cancer
Published: January 12, 2021
Showing 1-12 of 20

Last Updated: 09/26/2026